Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda. (2023)
Attributed to:
The impact of maternal infection with Mycobacterium tuberculosis on the infant response to BCG immunisation
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.vaccine.2023.10.055
PubMed Identifier: 37981473
Publication URI: http://europepmc.org/abstract/MED/37981473
Type: Journal Article/Review
Volume: 41
Parent Publication: Vaccine
Issue: 50
ISSN: 0264-410X